FDA Warning Letter

Penn Herb Company, Ltd.

CGMP/Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements/Adulterated

発出済み(対応中)栄養補助食品
発出日
2026.10.19
掲載日
2026.11.10
発行オフィス
Human Foods Program
MARCS-CMS 番号
734317
配達方法
Via Email
宛先
Mr. William Betz Jr.

本文(英語原文)


Delivery Method:
Via Email
Product:
Dietary Supplements

Recipient:
Recipient Name
Mr. William Betz Jr.
Recipient Title
President/Owner
Penn Herb Company, Ltd.

10601 Decatur Rd Ste 2
Philadelphia, PA 19154-3212
United States

Issuing Office:
Human Foods Program

United States


October 19, 2026

WARNING LETTER

CMS #734317

Dear Mr. Betz:

The U.S. Food and Drug Administration (FDA) conducted an inspection of your facility located at 10601 Decatur Rd Ste 2, Philadelphia, PA 19154 from May 12 through June 8, 2026. Based on inspectional findings and review of the product labels collected during the inspection, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov.

At the conclusion of the inspection on June 8, 2026, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We have not received a response to Form FDA 483 as of the date on this letter.

Adulterated Dietary Supplements

The inspection of your facility from May 12 through June 8, 2026, identified serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause the Ashwagandha Root, Mexican Sarsaparilla Root, and Black Walnut Hulls dietary supplement products manufactured at your facility to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.

Your significant violations of the CGMP requirements are as follows:

1. You failed to establish, for each component that you use in the manufacture of a dietary supplement, identity specifications and component specifications regarding limits on those types of contamination that may adulterate or may lead to adulteration of the finished batch of dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(b)(1) and (b)(3). Specifically:

  • You failed to establish identity specifications for the component Mexican Sarsaparilla Root (used in the production of your dietary supplement product Mexican Sarsaparilla Root); and the component Black Walnut Hulls, (used in the production of your dietary supplement Black Walnut Hulls), as required by 21 CFR 111.70(b)(1). Specifically, your firm's "Receiving and Component Analysis" document for the component Mexican Sarsaparilla Root in powder form, botanical name of Smilax officinalis, under "Gross Organoleptic Analysis” states that you confirm the identity by evaluating appearance (whole/cut/powder), color (light brown, reddish brown to pale brown), taste (mucilaginous, bitter, weak), and aroma (sweet, spicy). However, because other sarsaparilla-producing Smilax species share the same or similar organoleptic characteristics, including appearance, color, taste, and aroma, analysis of these organoleptic factors does not provide unique information specific to Smilax officinalis and therefore cannot, by itself, confirm the species-level identity of Smilax officinalis. Your firm's "Receiving and Component Analysis" document for the component Black Walnut Hulls in powder form, botanical name Juglans nigra, under “Gross Organoleptic Analysis” states that you confirm the identity by evaluating the appearance (whole/cut/powder), color (dark brown), taste (bitter, woody), and aroma (woody). However, because other botanical materials, including other Juglans species, share the same or similar organoleptic characteristics, including appearance, color, taste, and aroma, analysis of these organoleptic factors does not provide unique information specific to Juglans nigra. Therefore, these organoleptic characteristics alone are not sufficiently specific to confirm the species-level identity of your powdered Black Walnut Hulls component, botanical name Juglans nigra. You also include a link under identity verification process to a CoA sheet for Black Walnut Hull Powder Herb (b)(4), which includes additional organoleptic characteristics (aroma – earthy, slightly bitter, nutty). The additional attributes increase the descriptive detail of the component but do not provide sufficiently specific characteristics to distinguish and verify its botanical identity.
  • You failed to establish limits on those types of contamination that may adulterate or that may lead to adulteration of the finished batch of the dietary supplement, as required by 21 CFR 111.70(b)(3). Specifically, you have not established limits on contaminants such as microbes and heavy metals that may be present in your dietary ingredients Ashwagandha Root, Mexican Sarsaparilla Root, and Black Walnut Hulls.

In addition to establishing the required specifications, your firm must demonstrate whether such specifications are met, in accordance with 21 CFR 111.73 and 111.75.

2. You failed to establish product specifications for the identity, purity, strength, and composition of the finished batch of the dietary supplement, and for limits on those types of contamination that may adulterate, or that may lead to adulteration of, the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(e).

Specifically, you have not established finished product specifications including identity, purity, strength, and composition, and limits on contamination for your finished dietary supplements Ashwagandha Root, Mexican Sarsaparilla Root, and Black Walnut Hulls. The established specification listed on each BPR is the weight of material per capsule in milligrams. Weight of material per capsule is not a specification to determine the identity, purity, strength, composition, and limits of contamination for these finished dietary supplement products.

In addition to establishing the required finished product specifications, your firm must demonstrate whether the established specifications are met, in accordance with 21 CFR 111.73 and 111.75.

3. You failed to conduct all manufacturing operations in accordance with adequate sanitation principles, as required by 21 CFR 111.360. Specifically:

  • During the walkthrough of the processing rooms, our investigator observed debris from previous production runs on food-contact surfaces of your (b)(4) encapsulator, including in the filled capsule collection/ejection chute. Powder debris was observed on the floor, walls, and ceilings of the encapsulator room and other manufacturing rooms. Powder residue was observed in the same processing room following pre-operational cleaning and sanitation conducted by your production employee, and prior to the initiation of production of your dietary supplement Mexican Sarsaparilla Root, Lot (b)(4). Your inadequate sanitation procedures risk contaminating your products.
  • Our investigator observed residual dietary ingredient powder remaining after each encapsulation cycle which was being collected in a (b)(4) container for reuse in subsequent capsule production using a worn brush and other tools. The manufacturing employee stated that these tools were reused across production runs and cleaned between uses by spraying (b)(4) and wiping with a (b)(4). Collecting and reclaiming spilled or residual powder using worn, improperly sanitized tools, and introducing it back into production, is an unsanitary manufacturing practice that creates a significant risk of introducing foreign physical materials and microbial contamination into your finished dietary supplements.
  • The sanitizing agent used to clean the food contact surfaces of your (b)(4) encapsulator was identified as “(b)(4). The product labeling identified it solely as a “(b)(4)” intended for external use on (b)(4). You were unable to provide evidence demonstrating that this agent was safe and suitable for use on food-contact surfaces in a dietary supplement manufacturing environment.
  • The only employee hand-sink located outside of the individual manufacturing rooms was posted with an "Out of Order" sign at the time of inspection and during active production of dietary supplements.
  • Multiple opened bulk bags of dietary supplement ingredients in the warehouse were observed resealed with tape, with some bags exhibiting loose or failing tape closures with dust debris on the exterior surfaces.

This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.

This letter notifies you of our concerns and provides you with an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.

We also have the following comment:

Section 201(qq)) of the Act [21 U.S.C. 321(qq)] defines milk, egg, fish, Crustacean shellfish, sesame, tree nuts, wheat, peanuts, and soybeans, as well as any food ingredient that contains protein derived from one of these foods, with the exception of highly refined oils, as "major food allergens." We note that your Black Walnut Hulls dietary supplement product label declares "black walnut (hulls)" as an ingredient, but does not declare the major food allergen “tree nuts” (specifically walnut) present in the product, as required by section 403(w)(1) of the Act. We recommend that you review your labeling to confirm that allergen declarations for all ingredients are in compliance with the requirements of section 403(w) of the Act.

Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.

Your written reply should be directed to Rebecca Allen, United States Food and Drug Administration, Human Foods Program, Office of Enforcement, 5001 Campus Drive, College Park, Maryland 20740-3835 or via email at HFP-OCE-DietarySupplements@fda.hhs.gov. Please reference CMS #734317 on any submissions and within the subject line of any emails to us. If you have any questions, you may email at HFP-OCE-DietarySupplements@fda.hhs.gov.

Sincerely,
/S/

Maria S. Knirk, JD, MBA
Director, Office of Enforcement
Office of Compliance and Enforcement
Human Foods Program

無料会員 1,000名 突破

米国 FDA 警告書の全文閲覧は会員限定です

無料で会員登録する

出典: fda.gov(U.S. FDA)の Warning Letters 公開情報 (米国政府著作物としてパブリックドメイン)をそのまま掲載しています。内容の正確性・最新性は保証されません。FDA が本サイトの内容を承認・保証するものではありません。

Warning Letter の最新状態・Close-out(是正完了)の正は FDA 公式サイトです。是正が完了した企業には Close-out Letter が発行される場合があり、本サイトの表示が最新の状態を反映していないことがあります。掲載は事実の転載であり、企業の現在の法令遵守状況について評価・断定するものではありません。

取得日: 2026.11.17

各データセット(510(k)・PMA・MAUDE・回収・Warning Letter)の解説は 米国FDA情報の概要 を参照してください。